CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The HepaVac project aims to develop a therapeutic cancer vaccine for early-stage liver cancer patients following ablative therapy. By targeting specific tumor antigens, the project seeks to enhance immune responses and improve patient survival rates.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide.
Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%.
The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC patients after loco-regional ablative therapy.HepaVac is an European consortium of academic, SME and…
ISTITUTO NAZIONALE TUMORI Fondazione Pascale
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Varese
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, TUEBINGEN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
